Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s disease.
Mengel D, Soter E, Ott JM, Wacker M, Leyva A, Peters O, Hellmann-Regen J, Schneider LS, Wang X, Priller J, Spruth E, Altenstein S, Schneider A, Fliessbach K, Wiltfang J, Hansen N, Rostamzadeh A, Düzel E, Glanz W, Incesoy EI, Buerger K, Janowitz D, Ewers M, Perneczky R, Rauchmann B, Teipel S, Kilimann I, Laske C, Sodenkamp S, Spottke A, Brustkern J, Brosseron F, Wagner M, Stark M, Kleineidam L, Shao K, Lüsebrink F, Yakupov R, Schmid M, Hetzer S, Dechent P, Scheffler K, Berron D, Jessen F, Synofzik M; DELCODE study group.
Mengel D, et al. Among authors: teipel s.
Mol Psychiatry. 2025 Jul;30(7):3150-3159. doi: 10.1038/s41380-025-03021-0. Epub 2025 Apr 18.
Mol Psychiatry. 2025.
PMID: 40247130
Free PMC article.